Sign in
CompletedPhase 1/2

Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT

Key facts

Who runs it
Stanford University
Where
Stanford, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
82 people enrolled
Started
12 Aug 2020
Ended
19 Jun 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Apixaban 2.5 MG Oral Tablet
  • Enoxaparin 40Mg/0.4mL Prefilled Syringe
Record updated
22 June 2025

Who can take part

Age
18 years to 89 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adult (>18 years) women
  • Scheduled to undergo unilateral or bilateral microsurgical breast reconstruction with free abdominal flaps (i.e. muscle-sparing transverse rectus abdominis musculocutaneous [TRAM] and/or deep inferior epigastric artery perforator [DIEP]) flap)
  • Caprini score of 6 or greater
  • Ability to understand and the willingness to sign a written informed consent document

Who cannot take part

  • Active bleeding
  • History of bleeding disorder
  • History of coagulopathy
  • History of heparin-induced thrombocytopenia
  • History of liver disease
  • Uncontrolled hypertension
  • History of alcohol and/or substance abuse
  • History of renal disease (creatinine clearance <30 mL/min; serum creatinine >1.6 mg/dL)
  • Contraindication to the use of apixaban or enoxaparin
  • Major neurosurgical intervention (brain/spine) within the past 90 days
  • Ophthalmologic procedure within the past 90 days
  • Need for therapeutic anticoagulation
  • Pregnant or Nursing

Where in United States

  • Stanford University Medical CenterStanford, United States

About the trial

What the trial wants to find out

Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite guideline-compliant prophylaxis. A population at particular risk is the growing number of patients who undergo autologous breast reconstruction. Direct oral anticoagulants (DOAC) might be a less invasive, yet, more efficacious mode of chemoprophylaxis in this patient population. Hence, the proposed work has the potential to cause a paradigm shift in chemoprophylaxis guidelines in a large population of patients undergoing plastic surgery.

The 2 groups in the trial

  • ApixabanTreatment being tested

    Patients assigned to this group will receive Apixaban 2.5 mg PO BID starting 12 hours after completing skin closure.

    Treatment: Apixaban 2.5 MG Oral Tablet

  • EnoxaparinExisting treatment, for comparison

    Patients assigned to this group will receive Enoxaparin 40 mg SC QD starting 12 hours after completing skin closure.

    Treatment: Enoxaparin 40Mg/0.4mL Prefilled Syringe

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Controlled Trial Comparing Apixaban Versus Enoxaparin Following Microsurgical Breast Reconstruction
Record updated
22 June 2025